Deal of the Day — limited-time pharmacy picks!
Spegra Tablet

Spegra Tablet

Prescription requiredRx Required

Salt Composition: Tenofovir Alfenamide, Emtricitabine, Dolutegravir

Expiry Date: 01/2028

Special offer

Price on Request

Price on Request

Inclusive of all taxes

▼

30 Tablets in Bottle

About The Product

HIV

Spegra 50/200/25mg Tablet is a prescription-based antiretroviral or antiviral drug. It is used in the treatment of HIV (human immunodeficiency virus) infection. The active ingredients of Spegra are Dolutegravir, Emtricitabine, Tenofovir Alfenamide, which belong to the drug class of nucleoside reverse transcriptase inhibitors (NRTIs). This medicine work by increasing the immunity in adults and children above three years. Spegra Tablet is not the permanent cure for HIV, but it has the potential to reduce the chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related conditions.

Side Effects

  • Spegra Tablet shows some side effects.
  • Some of the mild ones do not need any medical attention, and they go away as the body adapts to the medicine.
  • It is important to consult your doctor if they persist for a longer time and are deteriorating your health.
  • Common side effects include: Nausea Diarrhea Vomiting Weight gain Headache Stomach pain Loss of strength Sleeplessness Tiredness and dizziness Autoimmune disorders Numbness or pain in the hands or feet High cholesterol and glucose levels in the blood Serious side effects are: Diabetes Liver problems Skin rash and itchin Unusual bleeding Inform your doctor immediately if you experience any persistent or unusual side effects.

How To Use

  • A doctor decides the recommended dose of Spegra 50/200/25mg Tablet according to your previous medical condition and response to the treatment.
  • It is advised to take this medicine after consulting your healthcare expert.
  • This medicine should be taken orally at the same time every day.
  • Please do not crush or chew the medicine and eat it as a whole with a glass of water.
  • This tablet can be taken with or without food.

How It Works

Spegra Tablet is a combination of three medicines Dolutegravir, Emtricitabine and Tenofovir Alafenamide. It is antiretroviral or antiviral drug used to treat people diagnosed with HIV infection.

This tablet works by inhibiting the replication process of HIV infection. It improves the immune system of the patient to fight against infection, controls the virus production, reduces the viral load in the body and slows down the growth of this disease and works on overall health.

Safety Advice

Alcohol
Avoid the consumption of alcohol while taking Spegra Tablet, as alcohol can reduce the effectiveness of the medicine and worsen the symptoms
Pregnancy
Spegra Tablet is safe for use during pregnancy if prescribed by the doctor. No dosage adjustment is necessary for this Tablet.
Breast Feeding
Spegra 50/200/25mg Tablet is probably not safe if you're breastfeeding. Kindly consult your doctor.
Driving
It is advisable not to drive or operate heavy machinery as you may feel dizzy after taking the Spegra 50/200/25mg Tablet.
Kidney
Consumption of Spegra Tablet should be avoided without informing the doctor if you have any kidney-related issues.
Liver
Consumption of Spegra Tablet should be avoided without informing the doctor if you have any kidney-related issues

Missed Doses

  • It is advised not to miss any scheduled dosage of the Spegra 50/200/25mg Tablet.
  • In case you miss a dose, consult your doctor immediately.
  • Don't overdose to compensate for the missed one.
  • Contact your doctor or any healthcare provider and seek medical attention immediately in such cases.

Quick Tips

It is advised to use effective birth control methods to avoid pregnancy. Some drugs can cause birth defects, miscarriage, or death to an unborn baby if the mother or father is using this medicine. Moreover, this medicine may pass to the unborn baby.


Consult your doctor if you observe symptoms such as abdominal pain, loss of appetite, dark urine, or yellowing of the eyes or skin. These symptoms indicate the presence of Jaundice in the body.


It is advised to tell your doctor about all medicines (multivitamins, herbal supplements) you're taking currently before starting your course with Spegra 50/200/25mg Tablet. There are chances that many drugs can interact, and some drugs should not be used together.


Inform your healthcare expert in case of a history of severe blood infection, active tuberculosis, liver problems, or any serious health disorder.

FAQs

Birth control is mandatory in order to avoid transmission of HIV infection to your partner and to avoid an unwanted pregnancy.

Reference

1. Patel, H., Shah, M.

P. A., Gajera, M.

R. J., & Patel, H.

D. (2021).

DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR SIMULTANEOUS DETERMINATION OF RELATED SUBSTANCES PRESENT IN THE PHARMACEUTICAL DOSAGE FORM OF EMTRICITABINE, TENOFOVIR ALAFENAMIDE AND DOLUTEGRAVIR. Towards Excellence, 13(3).

2. Rathod, S.

M., & Patel, P. U.

(2022). Chemometrics-assisted spectrophotometric method development and validation for simultaneous estimation of emtricitabine, tenofovir alafenamide fumarate, and dolutegravir sodium in dosage form.

Journal of Reports in Pharmaceutical Sciences, 11(1), 41-50. 3.

Venter, W. D., Sokhela, S., Simmons, B., Moorhouse, M., Fairlie, L., Mashabane, N., ... & Hill, A.

(2020). Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.

The lancet HIV, 7(10), e666-e676. 4.

Sax, P. E., Pozniak, A., Montes, M.

L., Koenig, E., DeJesus, E., Stellbrink, H. J., ... & Quirk, E.

(2017). Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.

The Lancet, 390(10107), 2073-2082. 5.

Deeks, E. D.

(2018). Bictegravir/emtricitabine/tenofovir alafenamide: a review in HIV-1 infection.

Drugs, 78(17), 1817-1828.

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026